Migraine Study in Adolescent Patients - Full Text View

Sponsor:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00843024

Purpose

This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old

Condition	Intervention	Phase
Migraine With or Without Aura Migraine Disorders Migraine Headache Migraine, Acute Migraine	Drug: Sumatriptan and Naproxen Sodium Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents

Resource links provided by NLM:

Genetics Home Reference related topics: familial hemiplegic migraine

MedlinePlus related topics: Headache Migraine

Drug Information available for: Naproxen Naproxen sodium Succinic acid Sumatriptan Sumatriptan succinate

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Number of Participants Who Were Pain Free at 2 Hours Post-dose [ Time Frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe. Participants with pain-free response were considered as those who had a reduction in migraine headache pain from moderate (score=2) or severe (score=3) at baseline to none (score=0) post-treatment, without the use of rescue medication (additional medication taken by participants for the treatment of migraine pain or associated symptoms) prior to or at 2 hours post-dose.

Secondary Outcome Measures:

Number of Participants Sustained Pain-free From 2-24 Hours [ Time Frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Participants with sustained pain-freedom were defined as those with pain-freedom at 2 hours post-dose that was maintained up to 24 hours post-treatment without the use of rescue medication.
Number of Participants Photophobia-free at 2 Hours Post-dose [ Time Frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
The number of participants who did not have photophobia (sensitivity to light) at 2 hours post dose was analyzed.
Number of Participants Phonophobia-free at 2 Hours Post-dose [ Time Frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
The number of participants who did not have phonophobia (sensitivity to sound) at 2 hours post dose was analzyed.
Number of Participants Pain-free at 1 Hour Post-dose [ Time Frame: 1 hour after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Participants with a pain-free response at 1 hour post-dose were considered as those who had a reduction in migraine headache pain from moderate (a score of 2) or severe (a score of 3) at baseline to none (a score of 0) post-treatment, without the use of rescue medication prior to or at 1 hour post dose.
Number of Participants Sustained Photophobia-free From 2-24 Hours [ Time Frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Participants with sustained freedom from photophobia were those with an absence of photophobia (sensitivity to light) from 2 to 24 hours post-dose without the use of rescue medication.
Number of Participants Sustained Phonophobia-free From 2-24 Hours [ Time Frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Participants with sustained freedom from phonophobia were those with an absence of phonophobia (sensitivity to sound) from 2 to 24 hours post-dose without the use of rescue medication.
Number of Participants Sustained Nausea-free From 2-24 Hours [ Time Frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Participants with sustained freedom from nausea were those with an absence of nausea from 2 to 24 hours post-dose without the use of rescue medication.
Number of Participants Who Used Rescue Medication From 2 to 24 Hours Post Dose [ Time Frame: 2 to 24 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with investigational product. Permitted rescue medications included oral naproxen sodium (maximum 15 mg/kg), oral over-the-counter pain reliever, and anti-emetics. This outcome measure included only participants who rescued from 2 to 24 hours post-dose, inclusive.
Number of Participants Who Used Their First Dose of Rescue Medication Through the Indicated Time Points [ Time Frame: Dosing to 24 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
Rescue medication was defined as an additional medication taken by participants for the treatment of migraine pain or associated symptoms within 24 hours of dosing with double-blind treatment. In addition to participants who rescued from 2 to 24 hours post-dose, inclusive, this outcome measure also included nine protocol violators who rescued < 2 hours post-treatment.
Number of Participants Nausea-free at 2 Hours Post-dose [ Time Frame: 2 hours after single dose of double-blind treatment (Randomization through Week 13) ] [ Designated as safety issue: No ]
The number of participants who did not have nausea at 2 hours post dose was analzyed.

Enrollment:	865
Study Start Date:	December 2008
Study Completion Date:	June 2010
Primary Completion Date:	May 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Sumatriptan and Naproxen 1 Sumatriptan succinate and naproxen sodium combination 10mg/60mg	Drug: Sumatriptan and Naproxen Sodium Sumatriptan succinate and naproxen sodium
Experimental: Sumatriptan and Naproxen 2 Sumatriptan succinate and naproxen sodium combination 30mg/180mg	Drug: Sumatriptan and Naproxen Sodium Sumatriptan succinate and naproxen sodium
Experimental: Sumatriptan and Naproxen 3 Sumatriptan succinate and naproxen sodium combination 85mg/500mg	Drug: Sumatriptan and Naproxen Sodium Sumatriptan succinate and naproxen sodium
Placebo Comparator: Placebo Placebo to match	Drug: Placebo Placebo to match

Detailed Description:

The purpose of this study is to determine whether the combination product, sumatriptan and naproxen sodium, is effective compared to placebo in the treatment of acute migraine in adolescent subjects 12-17 years old. Subjects will treat two migraine attacks over a ~25 week period.

Eligibility

Ages Eligible for Study:	12 Years to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria: Subjects eligible for enrollment in the study must meet all of the following criteria:

Subject is >/=12 years of age and </=17 years of age at the Screening Visit.
Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least two, but no more than eight attacks per month, for the six months prior to the Screening Visit is required. Attacks should last a minimum of three hours and be associated with moderate-to-severe headache pain.
Subject is able to distinguish migraine from other headaches (i.e., tension-type headaches).
Male or female subjects. Female subjects are eligible for participation in the study if they are:
1. Females of non-childbearing potential; or
2. Females of childbearing potential, and who have a negative urine pregnancy test at screening, and agree to use one of the GlaxoSmithKline (GSK)-specified highly effective methods for avoiding pregnancy
Any subject taking oral contraceptives at enrollment must be on a stable regimen for at least 2 months prior to screening.
Subject and subject's parent or legal guardian are able to read and write English or Spanish.
Subject is able to read, comprehend, and complete subject diaries.
Subject's parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study.
Subject is willing and able to provide Informed Assent prior to entry into the study (if required).

-

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:
1. Subject is < 74 pounds (33.3 kg).
2. Subject has ≥15 headache days per month in total (migraine, probable migraine, or tension-type), retinal (ICHD-II 1.4), basilar (ICHD-II 1.2.6), or hemiplegic migraine (ICHD-II 1.2.4), or secondary headaches.
3. Subject, in the investigator's opinion is likely to have unrecognized cardiovascular or cerebrovascular disease.
4. Subject has uncontrolled hypertension at screening or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker.
5. Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study.
6. Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with any of the above.
7. Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening.
8. Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study.
9. Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma.
10. Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized.
11. Subject has a recent history of regular use of opioids or barbiturates for treatment of their migraine headache and/or other non-migraine pain. Regular use is defined as an average of 4 days per month over the last 6 months.
12. Subject has taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal preparations containing St. John's Wort (Hypericum perforatum), anytime within the two weeks prior to screening through two weeks post treatment.
13. Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent.
14. Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease.
15. Subject is pregnant, actively trying to become pregnant, or breast feeding or subject is not willing to have pregnancy test(s).
16. Subject tests positive for illicit substances on toxicology screen, or has evidence of alcohol or substance abuse within the last year, or any concurrent medical or psychiatric condition which, in the investigator's judgment, will likely interfere with the study conduct, subject cooperation, or evaluation and interpretation of the study results, or which otherwise contraindicates participation in this clinical trial.
17. Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00843024

Show 75 Study Locations

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

More Information

Publications:

Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4;297(13):1443-54.

Responsible Party:	Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier:	NCT00843024 History of Changes
Other Study ID Numbers:	107979
Study First Received:	February 12, 2009
Results First Received:	January 22, 2011
Last Updated:	February 9, 2012
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

Migraine efficacy
Migraine headache
Adolescent migraine

TREXIMET
Sumatriptan succinate
Naproxen sodium

Additional relevant MeSH terms:

Headache
Migraine Disorders
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Naproxen
Sumatriptan
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics

Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Vasoconstrictor Agents
Cardiovascular Agents
Serotonin 5-HT1 Receptor Agonists

ClinicalTrials.gov processed this record on February 09, 2012